Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer.
Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer.
复制标题
DOI：
10.1054/bjoc.1999.1004
复制
发表时间：
2000-02
影响因子：
8.8
通讯作者：
Gore ME
中科院分区：
文献类型：
--
作者：
Eisen T;Boshoff C;Mak I;Sapunar F;Vaughan MM;Pyle L;Johnston SR;Ahern R;Smith IE;Gore ME
为了生长和转移，实体瘤必须通过新血管生成发展自己的血液供应。沙利度胺抑制编码肽分子（包括肿瘤坏死因子-α（TNF-α）和血管生成因子血管内皮生长因子（VEGF））的mRNA的加工。本研究调查了持续低剂量沙利度胺在各种晚期恶性肿瘤患者中的应用。66例晚期可测量癌症（19例卵巢癌、18例肾癌、17例黑色素瘤、12例乳腺癌）患者（37例女性和29例男性;中位年龄48岁;范围33-62岁）每晚口服沙利度胺100 mg，直至出现疾病进展或不可接受的毒性。18例肾癌患者中有3例显示部分缓解，另外3例患者的疾病稳定长达6个月。其他类型肿瘤无明显疗效，但在睡眠（P< 0.05）和食欲维持（P< 0.05）方面有明显改善。在治疗期间测定血清和尿液中碱性成纤维细胞生长因子（bFGF）、TNF-α和VEGF的浓度，较高水平与疾病进展相关。沙利度胺耐受性良好：2例患者发生WHO 2级周围神经病变，8例患者发生WHO 2级嗜睡。没有患者发生WHO 3级或4级毒性。进一步的研究评估使用沙利度胺在更高的剂量作为一个单一的药物治疗晚期肾癌和联合生物化疗方案是必要的。2000癌症研究运动
To grow and metastasize, solid tumours must develop their own blood supply by neo-angiogenesis. Thalidomide inhibits the processing of mRNA encoding peptide molecules including tumour necrosis factor-alpha (TNF-α) and the angiogenic factor vascular endothelial growth factor (VEGF). This study investigated the use of continuous low dose Thalidomide in patients with a variety of advanced malignancies. Sixty-six patients (37 women and 29 men; median age, 48 years; range 33–62 years) with advanced measurable cancer (19 ovarian, 18 renal, 17 melanoma, 12 breast cancer) received Thalidomide 100 mg orally every night until disease progression or unacceptable toxicity was encountered. Three of 18 patients with renal cancer showed partial responses and a further three patients experienced stabilization of their disease for up to 6 months. Although no objective responses were seen in the other tumour types, there were significant improvements in patients' sleeping (P< 0.05) and maintained appetite (P< 0.05). Serum and urine concentrations of basic fibroblast growth factor (bFGF), TNF-α and VEGF were measured during treatment and higher levels were associated with progressive disease. Thalidomide was well tolerated: Two patients developed WHO Grade 2 peripheral neuropathy and eight patients developed WHO grade 2 lethargy. No patients developed WHO grade 3 or 4 toxicity. Further studies evaluating the use of Thalidomide at higher doses as a single agent for advanced renal cancer and in combination with biochemotherapy regimens are warranted. © 2000 Cancer Research Campaign
登录
查看更多内容
影响因子：
8.8
作者：
Ching LM;Xu ZF;Gummer BH;Palmer BD;Joseph WR;Baguley BC
通讯作者：
Baguley BC
DOI：
10.1016/0030-4220(87)90006-5
发表时间：
1987-09-01
期刊：
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTOLOGY
影响因子：
--
作者：
EISENBUD, L;HOROWITZ, I;KAY, B
通讯作者：
KAY, B
影响因子：
5.8
作者：
KOO, AS;ARMSTRONG, C;BELLDEGRUN, A
通讯作者：
BELLDEGRUN, A
DOI：
10.1073/pnas.94.24.13203
发表时间：
1997-11-25
影响因子：
11.1
作者：
Schiffenbauer, YS;Abramovitch, R;Neeman, M
通讯作者：
Neeman, M
影响因子：
158.5
作者：
Jacobson, JM;Greenspan, JS;Wohl, DA
通讯作者：
Wohl, DA